1. Search Result
Search Result
Results for "

CaM

" in MedChemExpress (MCE) Product Catalog:

59

Inhibitors & Agonists

1

Fluorescent Dye

22

Peptides

1

Inhibitory Antibodies

4

Natural
Products

78

Recombinant Proteins

1

Isotope-Labeled Compounds

21

Antibodies

1

Click Chemistry

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150147
    CAM833
    1 Publications Verification

    RAD51 Apoptosis Cancer
    CAM833 is a potent orthosteric inhibitor of the interaction between BRCA2 and RAD51 with a Kd of 366 nM against the ChimRAD51 protein. CAM833 also inhibits RAD51 oligomerization. CAM833 increases the progression of G2/M-arrested cells into apoptosis .
    CAM833
  • HY-168022

    Aurora Kinase Cancer
    CAM2602 is an Aurora A-TPX2 interaction inhibitor that has a binding affinity of 19 nM to Aurora A. CAM2602 can inhibit the growth of pancreatic cancer cells. In solid tumor transplant models, CAM2602 can increase the proportion of PH3 positive cells while reducing the proportion of P-Thr288 Aurora A positive cells, thereby inhibiting tumor growth .
    CAM2602
  • HY-P99031

    CaM 3001

    c-Fms Cardiovascular Disease Inflammation/Immunology
    Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death .
    Mavrilimumab
  • HY-129810

    CaM 1028

    Cholecystokinin Receptor Neurological Disease
    PD 135158 (CAM 1028) is a selective CCKB receptor antagonist with an IC50 of 2.8 nM against mouse cortex CCKB. PD 135158 shows anxiolytic activity .
    PD 135158
  • HY-P10316

    Calmodulin-Dependent Protein Kinase I (299-320) Binding Domain

    CaMK Others
    CaMKI (299-320) refers to a peptide consisting of residues 299-320 of Calcium/calmodulin-dependent protein kinase I (CaMKI). CaMKI (299-320), as a protein kinase, has a high affinity interaction with Ca 2+-CAM (Kd≤1 nM≤1 nM), which can phosphorylate specific substrate proteins, thereby regulating their activity. CaMKI (299-320) contains the CAM-binding domain and the self-inhibition domain, and CaMKI (299-320) can be used to study cell physiological processes, including cell proliferation, differentiation, and apoptosis .
    CaMKI(299-320)
  • HY-120381

    CaM 1189

    Cholecystokinin Receptor Neurological Disease Inflammation/Immunology
    PD 136450 (CAM 1189) is an antagonist for cholecystokinin 2 (CCK2). PD 136450 exhibits anti-secretory, anxiolytic and anti-ulcer activities, inhibits gastric acid secretion (IC50=1 mg/kg), and ameliorates the haemorrhagic lesions (IC50=4.7 mg/kg) in rats .
    PD 136450
  • HY-169209

    ATM/ATR Cancer
    CA-M11 (compund CA-M11) can enter the liver area of bile salt transport and release Mirin .
    CA-M11
  • HY-P10071

    Calmodulin Kinase IINtide; CaM-KIIN; CaM-KIINβ

    CaMK Others
    CaMKII inhibitory peptide KIIN is a potent inhibitor of CaMKII .
    CaMKII inhibitory peptide KIIN
  • HY-142087

    Calmodulin Endogenous Metabolite Neurological Disease
    Beauverolide Ja, a cyclotetradepsipeptide, is a potent calmodulin (CaM) inhibitor with a Kd of 0.078 μM and a Ki of 0.39 μM for Ca 2+-CaM. Beauverolide Ja is a secondary metabolite of Isaria fumosorosea .
    Beauverolide Ja
  • HY-RS24545

    Small Interfering RNA (siRNA) Others

    L1cam Rat Pre-designed siRNA Set A contains three designed siRNAs for L1cam gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    L1cam Rat Pre-designed siRNA Set A
    L1cam Rat Pre-designed siRNA Set A
  • HY-RS18070

    Small Interfering RNA (siRNA) Others

    L1cam Mouse Pre-designed siRNA Set A contains three designed siRNAs for L1cam gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    L1cam Mouse Pre-designed siRNA Set A
    L1cam Mouse Pre-designed siRNA Set A
  • HY-RS07481

    Small Interfering RNA (siRNA) Others

    L1CAM Human Pre-designed siRNA Set A contains three designed siRNAs for L1CAM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    L1CAM Human Pre-designed siRNA Set A
    L1CAM Human Pre-designed siRNA Set A
  • HY-173091S

    Isotope-Labeled Compounds Others
    pyroE-QEAVEGGC(Cam)SHLGQSYADR-(Arg- 13C6, 15N4) TFA is the 13C- and 15N-labeled pyroE-QEAVEGGC(Cam)SHLGQSYADR-(Arg) TFA.
    pyroE-QEAVEGGC(Cam)SHLGQSYADR-(Arg-13C6,15N4) TFA
  • HY-124600
    NVR 3-778
    1 Publications Verification

    HBV Infection
    NVR 3-778 is a first-in-Class and oral bioavailable HBV CAM (capsid assembly modulator) belonging to the SBA (sulfamoylbenzamide) class, with anti-HBV activity .
    NVR 3-778
  • HY-P1075
    CALP3
    2 Publications Verification

    Calcium Channel Neurological Disease Cancer
    CALP3, a Ca 2+-like peptide, is a potent Ca 2+ channel blocker that activates EF hand motifs of Ca 2+-binding proteins. CALP3 can functionally mimic increased [Ca 2+]i by modulating the activity of Calmodulin (CaM), Ca 2+ channels and pumps. CALP3 has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .
    CALP3
  • HY-P1075A

    Calcium Channel Neurological Disease Cancer
    CALP3 TFA, a Ca 2+-like peptide, is a potent Ca 2+ channel blocker that activates EF hand motifs of Ca 2+-binding proteins. CALP3 TFA can functionally mimic increased [Ca 2+]i by modulating the activity of Calmodulin (CaM), Ca 2+ channels and pumps. CALP3 TFA has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .
    CALP3 TFA
  • HY-P3965

    Myosin Neurological Disease
    16-38-Thymosin β4 (cattle) is a Ca 2+-independent MLCK activator with high affinity .
    16-38-Thymosin β4 (cattle)
  • HY-P3965A

    Myosin Neurological Disease
    16-38-Thymosin β4 (cattle) TFA is a Ca 2+-independent MLCK activator with high affinity .
    16-38-Thymosin β4 (cattle) (TFA)
  • HY-19805A

    CaMK AMPK Autophagy Metabolic Disease
    STO-609 acetate is a selective and cell-permeable inhibitor of the Ca 2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 acetate inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC50 ~0.02 g/ml.
    STO-609 acetate
  • HY-19805
    STO-609
    Maximum Cited Publications
    20 Publications Verification

    CaMK AMPK Autophagy Metabolic Disease
    STO-609 is a selective and cell-permeable inhibitor of the Ca 2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC50 ~0.02 g/ml.
    STO-609
  • HY-P1076

    Calmodulin Inflammation/Immunology
    CALP2 is a calmodulin (CaM) antagonist ( (Kd of 7.9 µM)) with high affinity for binding to the CaM EF-hand/Ca 2+-binding site. CALP2 inhibits CaM-dependent phosphodiesterase activity and increases intracellular Ca 2+ concentrations. CALP2 potently inhibits of adhesion and degranulation. CALP2 is also a strong activator of alveolar macrophages .
    CALP2
  • HY-P1076A

    Calmodulin Inflammation/Immunology
    CALP2 TFA is a calmodulin (CaM) antagonist (Kd of 7.9 µM) with high affinity for binding to the CaM EF-hand/Ca 2+-binding site. CALP2 TFA inhibits CaM-dependent phosphodiesterase activity and increases intracellular Ca 2+ concentrations. CALP2 TFA potently inhibits of adhesion and degranulation. CALP2 TFA is also a strong activator of alveolar macrophages .
    CALP2 TFA
  • HY-P1077
    CALP1
    1 Publications Verification

    mGluR Phosphodiesterase (PDE) Apoptosis Calmodulin Inflammation/Immunology
    CALP1 is a calmodulin (CaM) agonist (Kd of 88 µM) with binding to the CaM EF-hand/Ca 2+-binding site. CALP1 blocks calcium influx and apoptosis (IC50 of 44.78 µM) through inhibition of calcium channel opening. CALP1 blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 activates CaM-dependent phosphodiesterase activity .
    CALP1
  • HY-P2471

    Calmodulin Neurological Disease
    Neurogranin (48-76), mouse is a peptide corresponding to residues 48-76 of Neurogranin. Neurogranin, a calmodulin-binding protein, is exclusively expressed in the post-synapse, and mediates NMDAR driven synaptic plasticity by regulating the calcium-calmodulin (Ca 2+-CaM) pathway .
    Neurogranin (48-76), mouse
  • HY-P1077A
    CALP1 TFA
    1 Publications Verification

    mGluR Phosphodiesterase (PDE) Apoptosis Calmodulin Inflammation/Immunology
    CALP1 TFA is a calmodulin (CaM) agonist (Kd of 88 µM) with binding to the CaM EF-hand/Ca 2+-binding site. CALP1 TFA blocks calcium influx and apoptosis (IC50 of 44.78 µM) through inhibition of calcium channel opening. CALP1 TFA blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 TFA activates CaM-dependent phosphodiesterase activity .
    CALP1 TFA
  • HY-112564
    JNJ-632
    2 Publications Verification

    HBV Infection
    JNJ-632 is a hepatitis B virus (HBV) capsid assembly modulator (CAM).
    JNJ-632
  • HY-120997

    Berbamine p-nitrobenzoate

    Calmodulin Cancer
    E6 Berbamine (Berbamine p-nitrobenzoate) is a potent calmodulin (CaM) antagonist. E6 Berbamine inhibits the activity of calmodulin (CaM)-dependent myosin light chain kinase (MLCK), with a Ki of 0.95 μM . E6 Berbamine also shows anti-leukemia activities, with an IC50 of 2.13 μM in K562 cells .
    E6 Berbamine
  • HY-19025

    Calmodulin Inflammation/Immunology
    CV-159 is a unique dihydropyridine Ca 2+ antagonist with an anti-calmodulin (CaM) action, and has antiinflammatory activities.
    CV-159
  • HY-A0257A

    CaMK Neurological Disease
    Prenylamine lactate is a calcium-modulating protein (CaM) antagonist that inhibits CaM-dependent enzymes and can slowly relax smooth muscle preparations. The effect of Prenylamine lactate on smooth muscle is not inhibited by the calcium agonist Bay K 8644 (HY-10588). Reports suggest that under low heart rate conditions, Prenylamine seems to enhance voltage-dependent transmembrane calcium currents .
    Prenylamine lactate
  • HY-110140

    CaMK Cardiovascular Disease Neurological Disease
    (E)-KN-93 phosphate is an inhibitor for Ca 2+/calmodulin-dependent protein kinase II (CaMK II) with IC50 of 9 μM and 3 μM, for CaMKIIδ monomer and CaMKIIδ dodecamer. (E)-KN-93 phosphate binds competitively with Ca 2+/CaM, and disrupts their interaction with CaMK II, and thus inhibits the CaMK II activation .
    (E)-KN-93 phosphate
  • HY-P1874

    Calmodulin Neurological Disease
    Calmodulin-Dependent Protein Kinase II (281-309) is a peptide of calcium/calmodulin-dependent protein kinase II (CaM-kinase II) .
    Calmodulin-Dependent Protein Kinase II (281-309)
  • HY-P5424

    Calmodulin Others
    RyR1(3614-3643) is a biological active peptide. (the absolutely conserved peptide corresponding to the CaM-binding domain of RyR1 in all vertebrates)
    RyR1(3614-3643)
  • HY-P10165

    Calmodulin Metabolic Disease
    MLCK Peptide is a fully reversible, high affinity (pM) CaM-binding peptide derived from smooth muscle myosin light-chain kinase .
    MLCK Peptide
  • HY-N10588

    10-epi-Nardoguaianone J

    Others Cancer
    Nardoguaianone K, a guaiane-type compound, can be isolated from Nardostachys chinensis roots. Nardoguaianone K cam be used in the research of pancreatic cancer .
    Nardoguaianone K
  • HY-106645

    Calmodulin Neurological Disease Inflammation/Immunology
    Cloxacepride is an orally active and potent antiallergic agent. Cloxacepride is a CaM (calmodulin) antagonist. Cloxacepride has anti-PCA (passive cutaneous anaphylaxis) activity .
    Cloxacepride
  • HY-A0257AR

    CaMK Neurological Disease
    Prenylamine (lactate) (Standard) is the analytical standard of Prenylamine (lactate). This product is intended for research and analytical applications. Prenylamine lactate is a calcium-modulating protein (CaM) antagonist that inhibits CaM-dependent enzymes and can slowly relax smooth muscle preparations. The effect of Prenylamine lactate on smooth muscle is not inhibited by the calcium agonist Bay K 8644 (HY-10588). Reports suggest that under low heart rate conditions, Prenylamine seems to enhance voltage-dependent transmembrane calcium currents .
    Prenylamine (lactate) (Standard)
  • HY-N6776R

    Potassium Channel Neurological Disease Cancer
    Prenylamine (lactate) (Standard) is the analytical standard of Prenylamine (lactate). This product is intended for research and analytical applications. Prenylamine lactate is a calcium-modulating protein (CaM) antagonist that inhibits CaM-dependent enzymes and can slowly relax smooth muscle preparations. The effect of Prenylamine lactate on smooth muscle is not inhibited by the calcium agonist Bay K 8644 (HY-10588). Reports suggest that under low heart rate conditions, Prenylamine seems to enhance voltage-dependent transmembrane calcium currents .
    Penitrem A (Standard)
  • HY-P1029
    MLCK inhibitor peptide 18
    4 Publications Verification

    Myosin CaMK Autophagy Others
    MLCK inhibitor peptide 18 is a myosin light chain kinase (MLCK) inhibitor with an IC50 of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.
    MLCK inhibitor peptide 18
  • HY-D0987

    Calmodulin Others
    Stains-All, a cationic carbocyanine dye, is a convenient probe to study the structural features of the individual calcium-binding sites of calmodulin (CaM) and related calcium-binding proteins (CaBP) .
    Stains-All
  • HY-N10198

    Endogenous Metabolite Calmodulin Cardiovascular Disease
    Acremonidin A is a potent calmodulin (CaM) inhibitor found in Purpureocillium lilacinum. Acremonidin A binds to the human calmodulin (hCaM) biosensor hCaM M124C-mBBr, with Kd of 19.40 nM .
    Acremonidin A
  • HY-P3944

    CaMK Neurological Disease
    Calmodulin Dependent Protein Kinase Substrate is a Ca 2+- and calmodulin (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate is a synthetic peptide substrate for protein kinases .
    Calmodulin Dependent Protein Kinase Substrate
  • HY-P0271

    CaMK Autophagy Neurological Disease
    Syntide 2, a Ca 2+- and calmodulin (CaM)-dependent protein kinase II (CaMKII) substrate peptide, selectively inhibits the gibberellin (GA) response, leaving constitutive and abscisic acid-regulated events unaffected .
    Syntide 2
  • HY-P0271A
    Syntide 2 TFA
    2 Publications Verification

    CaMK Neurological Disease
    Syntide 2 (TFA), a Ca 2+- and calmodulin (CaM)-dependent protein kinase II (CaMKII) substrate peptide, selectively inhibits the gibberellin (GA) response, leaving constitutive and abscisic acid-regulated events unaffected .
    Syntide 2 TFA
  • HY-P3943

    CaMK Neurological Disease
    Calmodulin Dependent Protein Kinase Substrate Analog is a Ca 2+- and calmodulin (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate Analog is a synthetic peptide substrate for protein kinases .
    Calmodulin Dependent Protein Kinase Substrate Analog
  • HY-15517B
    KN-92 hydrochloride
    5+ Cited Publications

    CaMK Cancer
    KN-92 hydrochloride is an inactive derivative of KN-93, without CaM kinase inhibitory activity. KN-92 hydrochloride is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93 .
    KN-92 hydrochloride
  • HY-P1805

    Calmodulin Neurological Disease
    Calmodulin Binding Peptide 1 is a high affinity (pM) CaM-binding peptide derived from smooth muscle myosin light-chain kinase (MLCK peptide), which strongly inhibits IP3-induced Ca 2+ release .
    Calmodulin Binding Peptide 1
  • HY-P10393

    ERα (295-311)

    Apoptosis Cancer
    ERα17p (ERα 295-311) is the epitope of the CaM binding site on the estrogen receptor α (ER), which interacts with calmodulin (CaM) in a calcium-dependent manner. ERα17p regulates the migration of cancer cells MCF-7, SK-BR-3, T47D, and MDA-MB-231 through Rho/ROCK and PI3K/Akt signaling pathways. ERα17p inhibits proliferations of breast cancer cells, induces apoptosis, and inhibits tumor growth in mouse models .
    ERα17p
  • HY-103319

    R 24571

    Autophagy Calmodulin Neurological Disease Cancer
    Calmidazolium chloride (R 24571) is a calmodulin antagonist, antagonizing CaM-dependent phosphodiesterase and calmodulin-induced activation of erythrocyte Ca2+-transporting ATPase with IC50s of 0.15 and 0.35 μM, respectively . Also in anti-cancer research . Calmidazolium binds to calmodulin with a Kd of 3 nM.
    Calmidazolium chloride
  • HY-15517A
    KN-92 phosphate
    5+ Cited Publications

    CaMK Autophagy Cancer
    KN-92 phosphate is an inactive derivative of KN-93, without CaM kinase inhibitory activity. KN-92 phosphate is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 is a cell-permeable, reversible and competitive CaMKII inhibitor .
    KN-92 phosphate
  • HY-15517
    KN-92
    5+ Cited Publications

    CaMK Cancer
    KN-92 is an inactive derivative of KN-93, without CaM kinase inhibitory activity. KN-92 is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 is a cell-permeable, reversible and competitive CaMKII inhibitor .
    KN-92

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: